Chimeric antigen receptor (CAR)-T cell therapy represents a landmark achievement in cancer immunotherapy. While viral vector-based CAR-T platforms have demonstrated remarkable clinical efficacy, their complex manufacturing processes and integration-related risks have motivated exploration of alternative approaches. Among them, mRNA-engineered CAR therapies offer distinctive advantages, enabling the generation of CAR-modified cells ex vivo or in vivo without permanent genomic alteration. The transient expression of mRNA not only enhances safety management but also provides flexibility for dose control and repeated administration. The achievement of this approach relies on advances in preparation technologies and optimization of key design parameters. This review summarizes the critical techniques supporting mRNA-engineered CAR-T therapy, including ex vivo electroporation methods, in vivo lipid nanoparticle (LNP) delivery systems, and mRNA design and optimization strategies. Building on these technological foundations, we further analyze the remaining translational barriers and highlight emerging opportunities that may accelerate the clinical development and broader application of mRNA-engineered CAR Therapies.